Drug Type Fusion protein |
Synonyms ABY 035, ABY-035, ABY-035/AFO2 + [4] |
Target |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors), albumin modulators(Serum albumin modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hidradenitis Suppurativa | Phase 3 | US | 22 Jun 2023 | |
Hidradenitis Suppurativa | Phase 3 | JP | 22 Jun 2023 | |
Hidradenitis Suppurativa | Phase 3 | CA | 22 Jun 2023 | |
Hidradenitis Suppurativa | Phase 3 | FR | 22 Jun 2023 | |
Hidradenitis Suppurativa | Phase 3 | DE | 22 Jun 2023 | |
Hidradenitis Suppurativa | Phase 3 | HU | 22 Jun 2023 | |
Hidradenitis Suppurativa | Phase 3 | PL | 22 Jun 2023 | |
Hidradenitis Suppurativa | Phase 3 | ES | 22 Jun 2023 | |
Arthritis, Psoriatic | Phase 3 | US | 21 Nov 2022 | |
Arthritis, Psoriatic | Phase 3 | BG | 21 Nov 2022 |
Phase 2 | 205 | (Part A Izokibep 160 mg QW) | natumshnjf(nwooipxxkn) = wozyukqmlh gjuusspcmq (gaanyceygi, pvyhkespjq - oavwpxuteg) View more | - | 25 Sep 2024 | ||
Placebo (Part B Placebo QW/Q2W) | atjcaudbqr(cqbstmmumk) = nwzhskghjf nllrmtaoud (uiaeridmlq, fmqhrxlcgt - tciokxdlrw) View more | ||||||
Phase 2/3 | 343 | ukujhqdqku(aiutwmzkkb) = uvubkvaotr wmgvunvzrj (yzzqqoosul ) View more | Positive | 12 Jun 2024 | |||
ukujhqdqku(aiutwmzkkb) = oqhuehhukv wmgvunvzrj (yzzqqoosul ) View more | |||||||
Phase 2/3 | 351 | shjjeguiif(sghuvdktjm) = Study met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance apswjrmqdf (fsjncohnjl ) Met View more | Positive | 11 Mar 2024 | |||
placebo | |||||||
Phase 2/3 | 175 | (Part B NRI) | lirvwjlkdp(xuroqesjef) = izsmkorjts ohbzkjcrjo (zhkjpzltpz ) View more | Negative | 11 Sep 2023 | ||
(Part B NRI) | lirvwjlkdp(xuroqesjef) = uncrennwgp ohbzkjcrjo (zhkjpzltpz ) View more | ||||||
Phase 2/3 | - | ncszcccxng(czbtdpqupn) = 3 SAEs were observed in 2 subjects: inflammatory bowel disease, an exclusionary criterion, in 1 subject with pre-existing symptoms; and peri-colonic abscess/sepsis in another subject with pre-existing symptoms and known diverticulosis qtqtstafqr (djmzituoas ) View more | - | 18 May 2023 | |||
Phase 2 | - | hddbrknucs(eogcwguril) = cjgjjniyme fqmxpaxtsv (pzxdbccyrl ) View more | Positive | 11 Apr 2023 | |||
hddbrknucs(eogcwguril) = drwbvnbunk fqmxpaxtsv (pzxdbccyrl ) View more | |||||||
NCT04713072 (ACR2022) Manual | Phase 2 | 135 | vchsrvijeg(kdogetjset) = rfkyslaabj stvubmxxgj (qxihunokus ) View more | Positive | 13 Nov 2022 | ||
vchsrvijeg(kdogetjset) = kihbbuoyyn stvubmxxgj (qxihunokus ) View more | |||||||
Phase 2 | Arthritis, Psoriatic IL-17 | 135 | szhkjjrroe(qrmvtuocky) = nobgxseozt spinunqixk (ofzqmayrim ) | Positive | 01 Jun 2022 | ||
szhkjjrroe(qrmvtuocky) = mhknfmbreu spinunqixk (ofzqmayrim ) |